|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis显示文摘AIM: To determine the clinical impact of portal vein thrombosis in terms of both mortality and hepatic decompensations(variceal hemorrhage, ascites, portosystemic encephalopathy) in adult patients with cirrhosis.METHODS: We identified original articles reported through February 2015 in MEDLINE, Scopus, Science Citation Index, AMED, the Cochrane Library, and relevant examples available in the grey literature. Two independent reviewers screened all citations for inclusion criteria and extracted summary data. Random effects odds ratios were calculated to obtain aggregate estimates of effect size across included studies, with 95%CI.RESULTS: A total of 226 citations were identified and reviewed, and 3 studies with 2436 participants were included in the meta-analysis of summary effect. Patients with portal vein thrombosis had an increased risk of mortality(OR = 1.62, 95%CI: 1.11-2.36, P = 0.01). Portal vein thrombosis was associated with an increased risk of ascites(OR = 2.52, 95%CI: 1.63-3.89, P < 0.001). There was insufficient data available to determine the pooled effect on other markers of decompensation including gastroesophageal variceal bleeding or hepatic encephalopathy. CONCLUSION: Portal vein thrombosis appears to increase mortality and ascites, however, the relatively small number of included studies limits more generalizable conclusions. More trials with a direct comparison group are needed. | Jonathan G Stine Puja M Shah Scott L Cornella Sean R Rudnick Marwan S Ghabril George J Stukenborg Patrick G Northup | 2015 | World Journal of Hepatology2015，7，27： | 42 |
| 2 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 3 | Guanylyl cyclase C signaling axis and colon cancer prevention显示文摘Colorectal cancer(CRC) is a major cause of cancerrelated mortality and morbidity worldwide. While improved treatments have enhanced overall patient outcome, disease burden encompassing quality of life, cost of care, and patient survival has seen little benefit. Consequently, additional advances in CRC treatments remain important, with an emphasis on preventative measures. Guanylyl cyclase C(GUCY2C), a transmembrane receptor expressed on intestinal epithelial cells, plays an important role in orchestrating intestinal homeostatic mechanisms. These effects are mediated by the endogenous hormones guanylin(GUCA2A) and uroguanylin(GUCA2B), which bind and activate GUCY2 C to regulate proliferation, metabolism and barrier function in intestine. Recent studies have demonstrated a link between GUCY2 C silencing and intestinal dysfunction, including tumorigenesis. Indeed, GUCY2 C silencing by the near universal loss of its paracrine hormone ligands increases colon cancer susceptibility in animals and humans. GUCY2C's role as a tumor suppressor has opened the door to a new paradigm for CRC prevention by hormone replacement therapy using synthetic hormone analogs, such as the FDA-approved oral GUCY2 C ligand linaclotide(Linzess^(TM)). Here we review the known contributions of the GUCY2 C signaling axis to CRC, and relate them to a novel clinical strategy targeting tumor chemoprevention. | Amanda M Pattison Dante J Merlino Erik S Blomain Scott A Waldman | 2016 | World Journal of Gastroenterology2016，22，36： | 2 |
| 4 | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders显示文摘 | E Joanna Baxter Linda M Scott Peter J Campbell Clare East Nasios Fourouclas Soheila Swanton George S Vassiliou Anthony J Bench Elaine M Boyd Natasha Curtin Mike A Scott Wendy N Erber Anthony R Green | 2005 | The Lancet . 2005 (9464)2005，，： | 2 |
| 5 | B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy显示文摘 | Vijay K Kuchroo Mercy Prabhu Das Julia A Brown Ann M Ranger Scott S Zamvil Raymond A Sobel Howard L Weiner Nasrin Nabavi Laurie H Glimcher | 1995 | Cell1995，，5： | 2 |
| 6 | Toward a unifying framework for exploring fit and flexibility in strategic human resource management显示文摘 | Patrick M W & Scott A S | 1998 | Academy of management review1998，23，： | 1 |
| 7 | Scrapie injected murine neuroblastoma cells produce proteaseresistant prion proteins 显示文摘 | Butler D A Scott M R D Prusiner S B | 1988 | J Virol1988，62，： | 1 |
| 8 | Expression of the angiogenetic factors, vascular endothelial cell growth factor, acidic and basic libroblast growth factor, tumor growth factor beta-1,plate let- derived endothelial cell growth factor, placenta growth factor, and pleiotophin in human primary breast cancer and its relation to angiogenesis显示文摘 | RELF M LEJEUNE S SCOTT PAE | 1997 | Cancer Res1997，57，： | 1 |
| 9 | Changes in growth factor and cytokine mRNA levels after hepatectomy in rat with CCL4-induced cirrhosis显示文摘 | Masson S Scotte M Francois A | 1999 | Am J Physiol1999，277，41： | 1 |
| 10 | An exploration of the meaning and consequences of workaholism显示文摘 | Scott K S Moore K S Miceli M P | 1997 | Human Rela- tions1997，50，： | 1 |
| 11 | A pilot-scale continuous-jet hydrate reactor显示文摘 | Phillip S Scott D M Patricia T S | | 0，，： | 1 |
| 12 | An FFT- based approach for fast acquisition in spread spectrum communication systems显示文摘 | Spangenberg S M Scott I McLaughlin S | 2000 | Wireless Personal Communi- cations2000，13，12： | 1 |
| 13 | Comparison of column phases for separation of derivatized trichothecenes by capillary gas chromatography显示文摘 | Scott P M Kanhere S R | 1986 | Journal of Chromatography1986，368，2： | 1 |
| 14 | Three-dimensionally ordered macroporous Li4Ti5O12:effect of wall structure on electrochemical properties显示文摘 | Erin M S Scott J B Jung H K | 2006 | Chem Mater2006，18，2： | 1 |
| 15 | Oil source rock potential of the lacustrine Jurassic Sinuiju formation, western Korea BayBasin显示文摘 | Massoud M S Kinops S D Scott A C | 1994 | Offshore Oil1994，14，1： | 1 |
| 16 | The significance of metal hyeraccumalation for biotc interactions 显示文摘 | ROBERT S B SCOTT N M | 1998 | Chem Ecology1998，8，： | 1 |
| 17 | Sequence-tagged site markers for mic- rosatellite : simplified techniques for rapidly obtaining flanking sequences 显示文摘 | Thomas M R Scott N S | 1994 | Planr Mol Biol Rep1994，12，： | 1 |
| 18 | Numerically converged solutions of the global primitive equations for testing the dy- namical core of atmospheric GCMs 显示文摘 | Polvani L M Scott R K Thomas S J | 2004 | Mon Wea Rev2004，132，： | 1 |
| 19 | Intramuscular paliperidone palmitata 显示文摘 | Hoy S M Scott L J Keating G M | 2010 | CNS Drugs2010，24，3： | 1 |
| 20 | Partial cloning and ex-pression of the bovine Leptin gene显示文摘 | Ji S Q Wills G M Scott R R | 1998 | Animal Bi- otechnology1998，9，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员